CURE Pharmaceutical Holding Corp

(CURR, OTCQB)

$0.79

-$0.03
(-0.04%)
PE Ratio
0.00
EPS
-$1.01
Market Cap
$49M
52 Week Range
$0.71 - $2.65
Operating Margin
-642.57%
Dividend & Yield
$0 (0.00%)
Volume
NaN
Rev. per Share
$0.0430

About CURE Pharmaceutical Holding Corp

CURE Pharmaceutical Holding Corp., together with its subsidiaries, operates as an integrated drug delivery and development company in the United States and internationally. It focuses on the development and manufacture of drug formulation and drug delivery technologies in novel dosage forms to enhance drug efficacy, safety, and patient adherence. The company operates through two business segments: Cure and Sera Labs. It offers pharmaceutical and wellness products, including CUREfilm Blue, a sildenafil oral thin film for the treatment of erectile dysfunction; cannabinoid products with optimized pharmacokinetic profiles using microCURE and CUREfilm technology under the CUREfilm Canna name; and CUREfilm Anti-Viral, an orally bio-available anti-viral of an existing therapeutic leveraging existing pre-clinical/clinical safety and toxicity data. The company also provides CUREfilm Central Nervous System, a novel dosage form to treat disease states utilizing its proprietary CUREfilm dosage form, as well as to treat mental health disorders, such as depression, PTSD, addiction disorders, obsessive compulsive disorders, and anxiety. It sells wellness products through direct to consumer and wholesale channels. CURE Pharmaceutical Holding Corp. has a collaboration with Canopy Growth Corporation for the production and sale of medical cannabis. The company was founded in 2011 and is based in Oxnard, California.

Earnings

News about CURE Pharmaceutical Holding Corp

CURE Pharmaceutical Holding Corp

Type
Sector
Healthcare
Industry
Drug Manufacturers-Specialty & Generic
About kinfo
Kinfo is an app for DIY traders and investors. Kinfo tracks your trading performance and lets you compare measurable performance metrics against other traders. Kinfo works for day trading, swing trading and longer holding periods. By tracking portfolio performance kinfo allows traders to learn, find inspiration and gain confidence.
Get Social
Download the App

Trading involves significant risk of loss. It is not suitable for all investors and you should make sure you understand the risks involved, seeking independent advice if necessary.

Never risk more than you are willing to lose. Trading futures and other derivatives may cause losses that exceed deposits.

Hypothetical performance results have inherent limitations, some of which are described below. Kinfo makes no representation that any trading account will or is likely to achieve profits or losses like those shown. There are often sharp differences between hypothetical trading performance results and the actual results subsequently achieved by any trading program. Past results of advertised trading systems, profit statements, charts or any other representations are not indicative of future performance.

Kinfo is an educational site and is not a financial adviser or broker. All stocks, ETFs, commodities, Indices, Forex, Bonds, and other securities mentioned in our courses are for educational and illustrative purposes only. If you need professional investment advice, please consult a registered investment adviser. Futures and Options carry risk and may not be suitable for everyone.

Kinfo demonstrates specific advanced approaches (or methods). Any mention of Return of Investment percentages is only indicative of the potential of the strategy or the system and is not meant to signify any guaranteed returns.

Success in trading involves a range of human factors like decision making skills, adjustment skills, emotional control, and risk management and other psychological and behavioral parameters, all of which are completely in the hands of the individual. Trading involves significant risk of loss. It is not suitable for all investors.

Charts on kinfo provided by TradingView